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Introduction 
There has been increasing interest in the role of tumour location in the treatment and 
prognosis of patients with colorectal cancer (CRC), specifically in the adjuvant setting. 
Together with genomic data this has led to the proposal that right-sided and left-sided 
tumours should be considered as distinct biological and clinical entities. The aim of the 
present study was to examine the relationship between tumour location, tumour 
microenvironment, systemic inflammatory response (SIR), adjuvant chemotherapy and 
survival in patients undergoing potentially curative surgery for stage I-III colon and rectal 
cancer. 
Methods 
Clinicopathological characteristics were extracted from a prospective database. MMR and 
BRAF status was determined using immunohistochemistry. The tumour 
microenvironment was assessed using routine H&E pathological sections. SIR was assessed 
using mGPS, NLR, NPS and LMR.  
Results 
972 patients were included. The majority were over 65 years (68%), male (55%), TNM stage 
II/III (82%). 40% of patients had right-sided tumours, 31% had rectal cancers. Right-sided 
tumour location was associated with, older age (p=0.0001), deficient MMR (p=0.005), higher 
T stage (p=<0.001), poor tumour differentiation (p=<0.001), venous invasion (p=0.021) and 
high CD3+ within cancer cell nests (p=0.048). Right-sided location was consistently 
associated with a high SIR, mGPS (p=<0.001) and NPS (p=<0.001). There was no 
relationship between tumour location, adjuvant chemotherapy (p=0.632) or cancer-specific 
survival (CSS) (p=0.377). In those 275 patients who received adjuvant chemotherapy; right-
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sided location was not associated with MMR status (p=0.509) but was associated with higher 
T stage (p=0.001), venous invasion (p=0.036), CD3+ at the invasive margin (p=0.033) and 
CD3+ within cancer nests (p=0.012). There was no relationship between tumour location, SIR 
or CSS in the adjuvant group.  
Conclusion 
Right-sided tumour location was associated with an elevated tumour lymphocytic infiltrate 
and an elevated SIR. There was no association between tumour location and survival in the 
non-adjuvant or adjuvant setting in patients undergoing potentially curative surgery for stage 
I-III colon and rectal cancer. 
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Introduction 
Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the second 
most common in women with over half of cases occurring in developed nations (Ferlay et 
al.2012). In the United Kingdom five-year survival for patients diagnosed with CRC is 
approximately sixty percent (Cancer Research UK, 2011). Several population-based studies 
and data from clinical trials have reported that primary tumour location provides prognostic 
value in terms of patient survival. Over the last few decades most epidemiological studies 
from western populations report a continued rightward shift of colorectal cancer (Fleshner et 
al. 1989; Cucino et al. 2002; Alley & McNee 1986). Cancers of the right colon are more 
likely to be diagnosed in patients who are older and female; they are associated with locally 
advanced tumours, with greater mucinous component, poor differentiation  deficient 
mismatch repair (MMR) and BRAF V600E mutation (Fleshner et al. 1989; Alley & McNee 
1986; Weiss et al. 2016; Gelsomino et al. 2016; Clarke & Kopetz 2015). 
The clinical and biological distinction between colon and rectal cancer is widely recognised. 
Although several studies report that right- and left-sided colonic tumours should be 
considered as a distinct biological entity, the debate about the clinical relevance of this is 
ongoing. Moreover, the clinical utility of this distinction remains unclear with little evidence 
of its relevance to patients with stage I-III potentially curable colon cancer in terms of 
diagnosis, treatment and follow-up. The benefit of fluorouracil based adjuvant therapy in 
CRC is widely recognised, however in metastatic disease it would appear that right-sided 
colonic tumours are less responsive to such chemotherapy (Venook et al. 2016). Therefore, a 
plausible hypothesis is that the prognostic value of tumour location in patients with operable 
colorectal cancer is dependent on other unmeasured confounding factors. There is a 
substantial body of evidence which recognises systemic inflammation (Woo et al. 2015; Li et 
al. 2014)  and the tumour microenvironment as important determinants of disease progression 
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and outcome in both colon and rectal cancer. Inflammation based prognostic scores that 
evaluate the systemic inflammatory response (Li et al. 2014; Park et al. 2016) and the tumour 
microenvironment (Roxburgh & McMillan 2012; Klintrup et al. 2005) have yielded 
prognostic value independent of the widely used TNM staging system and so are candidates 
as potential confounding factors. The aim of the present study was to examine the 
relationship between tumour location, tumour microenvironment, systemic inflammation, 
adjuvant therapy and survival in patients undergoing potentially curative surgery for stage I-
III colon and rectal cancer. 
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Patients and methods 
Clinicopathological characteristics 
Patients were identified from a prospectively collated database of patients undergoing surgery 
for colorectal cancer in a single surgical unit at the Glasgow Royal Infirmary between 1997 
and 2016. Patient exclusions were based on the following criteria: metastatic disease 
including those patients with peritoneal involvement, emergency surgery, surgery with 
palliative intent, surgery for inflammatory bowel disease related malignancy, neoadjuvant 
chemoradiotherapy (excluded due to the potential immunological impact on the tumour 
microenvironment), familial cancer syndrome, underlying inflammatory condition or 
mortality within 30 days of surgery. Patients with tumours proximal to the splenic flexure 
were considered as right-sided. Tumours were staged according to conventional TNM 
classification with additional data retrieved from pathological reports issued after resection. 
Routine pathological elastica staining was used to assess the presence of venous invasion 
(Roxburgh et al. 2010). Following surgery patients were discussed at a local multi-
disciplinary meeting. Those patients undergoing colonic or rectal surgery with stage III or 
high-risk stage II disease without significant comorbidity, were offered 5- fluorouracil-based 
adjuvant chemotherapy with or without oxaliplatin, based on guidelines at the time.  
Patients were routinely followed up for 5 years after surgery. Date and cause of death was 
crosschecked with the cancer registration system and the Registrar General (Scotland). Death 
records were complete until 1st May 2016, this acted as the censor date for survival analysis. 
Cancer-specific survival (CSS) was measured from date of surgery until date of death from 
recurrent or metastatic colorectal cancer. Overall survival (OS) was measured from date of 
surgery until date of death from any cause. 
The West of Scotland Research Ethics Committee approved the study. 
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Assessment of MMR and BRAF status  
A subset of the patients in the full cohort underwent evaluation of MMR status, BRAF status 
and assessment of the tumour microenvironment. Using immunohistochemistry, a previously 
constructed tissue microarray comprising cores of formalin-fixed paraffin embedded cancer 
tissue was used to assess MMR and BRAF status. Immunohistochemistry for MMR status 
was previously described (Park et al. 2016). MMR protein expression was reported as MMR 
competent or deficient by a single blinded observer.  
For assessment of BRAF status tissue microarrays were dewaxed in xylene and rehydrated 
with graded alcohols.  Antigen retrieval was performed using Tris-EDTA buffer at pH9 under 
pressure for 5 minutes. Endogenous peroxidase activity was blocked using 3% hydrogen 
peroxide for 10 minutes. 10% Casein was applied for 20 minutes as a blocking solution. 
Tissue microarrays were incubated overnight at 4oC with anti-human BRAF V600E mouse 
monoclonal antibody (clone VE1, Spring Biosciences, US) at a concentration of 1:200. After 
washing in TBS, Envision (Dako) was applied for 30 minutes at room temperature before 
washing in TBS again. DAB substrate was added for 5 minutes until colour developed before 
washing in running water for 10 minutes. Slides were then counterstained in haematoxylin for 
60 seconds and blued with Scotts’ tap water before being dehydrated through a series of 
graded alcohols. Cover slips were applied using distrene, plasticizer, xylene (DPX). BRAF 
V600E mutation was reported as absent or present by a single blinded observer. 
Assessment of the tumour microenvironment 
Assessment of the tumour microenvironment was performed using routine haematoxylin and 
eosin-stained tissue sections. Klintrup-Mäkinen (KM) score (low/high) and extent of tumour 
stroma was assessed using tumour stroma percentage (≤50% = low or ≥50% = high), both 
previously described (Klintrup et al. 2005; Mesker et al. 2007). Tissue sections were also 
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used to assess lymphocytic tumour infiltrate. Immunohistochemistry for CD3+ (mature) and 
CD8+ (cytotoxic) T-lymphocytes was performed as per methodology previously described 
(Richards et al. 2014). T-lymphocyte density at the invasive margin and within the cancer cell 
nests was semi-quantitatively graded as low or high. Investigators were blinded to clinical 
data, pathological data and survival outcome.  
All cases were co-scored by a second investigator to ensure consistency of scoring. 
 Assessment of the systemic inflammatory response 
Serum CRP, albumin and differential white cell count were measured within 30 days prior to 
surgery and recorded prospectively. Pre-operative systemic inflammatory responses were 
defined using the modified Glasgow Prognostic Score (mGPS), the neutrophil:lymphocyte 
ratio (NLR), the neutrophil:platelet score (NPS) and lymphocyte:monocyte ratio (LMR). The 
mGPS was constructed as described previously (McMillan, 2013)  (patients with CRP ≤10 
mg/L scored 0, CRP > 10mg/L scored 1 and CRP > 10mg/L and albumin < 35g/L scored 2). 
On the basis of previously published thresholds, NLR>5 was considered elevated (Guthrie et 
al. 2013). The NPS was calculated as previously described (Watt et al. 2015), platelet 
count<400x109/L and neutrophil count <7.5x109/L scored 0, either a neutrophil 
count>7.5x109/L or platelet count>400x109/L scored 1, and those with elevated neutrophils 
and platelets scored 2. LMR was considered as either low (≤ 2.38) or high (>2.38) as 
previously described (Chan et al. 2017).  
 
Statistical analysis 
The association between tumour location and clinicopathological characteristics, measures of 
the tumour microenvironment and measures of systemic inflammation were analysed using 
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the Chi-squared test. 5-year cancer specific and overall survival was examined using Kaplan-
Meier log-rank survival analysis and univariate Cox-proportional hazards regression to 
calculate hazard ratios (HR) and 95% confidence intervals (95% CI). Variables found to be 
statistically significant (p<0.05) on univariate analysis were entered into a Cox regression 
multivariate model using a backward conditional method. A p value of <0.05 was considered 
to be significant. Analyses were performed using SPSS software version 21 (IBM SPSS). 
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Results 
Full Cohort 
972 patients who underwent elective surgery with curative intent for stage I-III colorectal 
cancer between January 1997 and 2016 were included in the analysis. Clinical and 
pathological features are shown in Table 1. Two thirds of the patients included were over the 
age of sixty-five and 55% were male. 178 (18%) patients had TNM stage I disease, 437 
(45%) had stage II disease and 356 (37%) patients had stage III disease. 81 patients (16%) 
with stage II disease and 196 (45%) patients with stage III disease received adjuvant 
chemotherapy. In the first decade 24 (12%) patients with stage II and 64 (37%) patients with 
stage III disease underwent adjuvant chemotherapy. In the latter decade this increased to 57 
(18%) patients with stage II and 132 (51%) patients with stage III disease. 389 (40%) patients 
had tumours located within the right colon, 285 (29%) within the left colon and 298 (31%) 
had rectal cancer.  
In terms of clinicopathological characteristics, right-sided tumour location was associated 
with older age (p=0.001), higher T stage (p=<0.001), high venous invasion (p=0.021), poor 
tumour differentiation (p=<0.001) and MMR deficiency (p=0.005) but was not associated 
with ASA (American Society of Anesthesiology) grade (p=0.088), nodal stage (p=0.320), 
marginal involvement (p=0.466), tumour necrosis (p=0.422) or BRAF status (p=0.566). 
Tumour location was not associated with the administration of adjuvant chemotherapy 
(p=0.632).  
When the tumour microenvironment was considered, there was no association between 
tumour location and Klintrup- Mäkinen Grade (p=0.431) or tumour stroma percentage 
(p=0.543). Right sided tumour location was associated with high CD3+ within cancer cell 
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nests (p=0.048) but not at the margin (p=0.160). Right-sided tumour location was not 
associated with CD8+ within cancer cell nests (p=0.666) or at the tumour margin (p=0.194). 
When the preoperative systemic inflammatory response was considered; right-sided tumour 
location was associated with a greater systemic inflammatory response as measured by the 
mGPS (p=<0.001) and NPS (p=<0.001). Right-sided tumour location was associated with a 
low preoperative LMR (p=0.005) (Table 1).  
The relationship between right-sided tumour location and the systemic inflammatory 
response was examined separately in T1/2, T3 and T4 tumours in the whole cohort. In those 
patients with T1/2 tumours, right-sided tumour location was not associated with mGPS 
(p=0.404), NLR (p=0.393), NPS (p=0.247) or LMR (p=0.137). In those patients with T3 
tumours, right-sided tumour location was directly associated with NPS (p=0.001) but was not 
associated with mGPS (p=0.119), NLR (p=0.514), or LMR (p=0.299). In those patients with 
T4 tumours, right-sided tumour location was directly associated with mGPS (p=0.025), NPS 
(p=0.020) and inversely with LMR (p=0.015).  
The median follow-up of survivors at time of censor was 54 months (interquartile range: 28 - 
107 months), with 192 cancer-related deaths and 188 non-cancer-related deaths. Right-sided 
tumour location was not associated with CSS (p=0.377) or OS (p=0.205) (Table 1) 
Univariate analysis in colon cancer patients 
On univariate analysis in patients with colonic cancer, age (p=0.001), ASA grade (p= 
<0.001), T stage (p=<0.001), N stage (p=<0.001), venous invasion (p=0.002), CD3+ within 
nests (p=0.001), mGPS (p=<0.001), NLR (p=0.007) and NPS (p=<0.001) were associated 
with reduced CSS. Sex, MMR status, tumour differentiation, LMR and tumour location (i.e. 
left or right colon) were not associated with CSS on univariate analysis. On multivariate 
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analysis, ASA grade (HR 1.91, p=0.035), N stage (HR 2.96, p=<0.001) and NPS (HR 2.35, 
p=0.005) were independently associated with reduced CSS. 164 (24%) patients with colon 
cancer underwent adjuvant chemotherapy. On univariate analysis in this group, T stage 
(p=0.006), mGPS (p=0.002) and NPS (p=0.010) were associated with reduced CSS. Age, 
ASA grade, N stage, tumour differentiation, venous invasion, CD3+ within cancer nests, 
NLR, LMR and tumour location were not associated with CSS on univariate analysis. On 
multivariate analysis mGPS (HR 1.77, p=0.050) was independently associated with reduced 
CSS in patients with colon cancer who had undergone adjuvant chemotherapy. 
Adjuvant chemotherapy group 
There were 275 patients in the adjuvant group who had undergone elective surgery followed 
by adjuvant chemotherapy with data available regarding tumour subsite. 96 (35%) of those 
patients had primary tumours located within the right colon, 68 (25%) within the left colon 
and 111 (40%) within the rectum. Clinicopathological characteristics are shown in Table 2. In 
terms of patient characteristics, tumour location was not associated with age (p=0.583), sex 
(p=0.139) or ASA grade (p=0.711). Right-sided tumour location was associated with higher 
T stage (p=<0.001), poor tumour differentiation (p=0.058) and high venous invasion 
(p=0.036) but not with nodal stage (p=0.398), margin involvement (p=0.423), tumour 
necrosis (p=0.779), MMR status (p=0.509) or BRAF status (p=0.460). 
When the tumour microenvironment was considered, tumour location was not associated with 
the Klintrup- Mäkinen Grade (p=0.285) or tumour stroma percentage (p=0.875). Right-sided 
tumour location was associated with high CD3+ at the margin (p=0.033) and within cancer 
cells nests (p=0.012) but was not associated with CD8+ density at the margin (p=0.586) or 
within cancer cell nests (p=0.522).  
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There was no association between tumour location and the systemic inflammatory response 
as measured by mGPS (p=0.597), NLR (p=0.183), NPS (p=0.066) or LMR (p=0.128).  
The median follow-up of survivors at time of censor was 56 months (interquartile range: 32 - 
101), with 60 cancer-related deaths and 27 non-cancer-related deaths. There was no 
significant difference in terms of CSS (p=0.302) or OS (p=0.076) in the adjuvant group 
(Table 2).  
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Discussion 
The results of the present study show that although right-sided tumour location was 
associated with factors pertaining to the host, tumour phenotype and features of the tumour 
microenvironment, it was not prognostic in terms of survival for patients undergoing surgery 
for stage I-III colon cancer or indeed for those patients within the adjuvant setting. Therefore, 
the importance of tumour location as a stratification factor in patients with colorectal cancer 
may be secondary to such tumour and host factors.  
In the present study, right-sided tumour location was associated with advancing age. Also, 
consistent with previous studies, right-sided tumour location was associated with a greater 
proportion of T4 tumours, poor tumour differentiation and presence of venous invasion 
(Weiss et al. 2016; Benedix et al. 2011; Nawa et al. 2008; Benedix et al. 2010). For example, 
Benedix and co-workers reported that, in 17,641 patients over a three-year period, right-sided 
colon cancer was more frequently diagnosed in women, older individuals, those with higher 
ASA grade, locally advanced and lymph node positive disease (Benedix et al. 2010). 
In the present study, twenty five percent of right-sided tumours were MMR deficient 
compared with eleven and eight percent of those tumours located within the left colon and 
rectum, confirming the findings of other studies which report the association of MMR 
deficiency with right-sided tumour location (Ward et al. 2001). Surprisingly MMR status was 
not associated with survival in the full cohort or the adjuvant setting. However, MMR status 
was only available in a subset of patients (n=228). Previous studies have reported the survival 
benefit conferred by MMR deficiency in the adjuvant setting (Ward et al. 2001; Tejpar et al. 
2009; Sinicrope et al. 2013). For example, Sinicrope and co-workers study of 2,580 patients 
in the adjuvant setting, reported the prognostic impact of MMR deficiency depended on 
tumour site, where deficient MMR cancers in the right colon had favourable outcomes 
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compared to those in the left colon (Sinicrope et al. 2011). Therefore, the lack of prognostic 
value of MMR in the present study is likely due to the small number of patients examined.  
In CRC, the local tumour inflammatory response has been reported as having prognostic 
value independent of tumour stage (Galon et al. 2006; Roxburgh et al. 2009). The 
relationship between MMR status, systemic inflammation and tumour lymphocytic infiltrate 
has been examined previously in this cohort. This previous study showed MMR was 
associated with the local immune tumour infiltrate and the systemic inflammatory response 
however, MMR had relatively poor prognostic value in comparison to these factors (Park et 
al. 2016). Our results suggest a significant association between right-sided tumour location 
and high density of activated T lymphocytes in the whole cohort and in the adjuvant therapy 
group. This observation may be explained in part by the association of defective mismatch 
repair with proximal tumour location and in turn with a coordinated, adaptive intratumoural 
immune response (Park et al. 2016). Nevertheless, the present study is the first to examine the 
relationship between tumour location and the tumour microenvironment.  
The results of the present study showed that for the first time, right-sided tumour location was 
consistently associated with an elevated systemic inflammatory response as measured by 
mGPS, NPS and LMR. The basis of this observation is not clear. However, in the present 
study right-sided tumour location was associated with higher T stage and previous reports 
suggest higher T stage is associated with increasing systemic inflammatory response hence, T 
stage may be a potential confounder. Therefore, in the present study, the relationship between 
right-sided tumour location and the systemic inflammatory response was examined separately 
in T1/2, T3 and T4 tumours in the whole cohort. In those patients with T1/2 tumours right-
sided tumour location was not associated with the systemic inflammatory response. In 
contrast, in those patients with T3 and T4 tumours, right sided tumour location was 
associated with the systemic inflammatory response (mGPS, NPS and LMR). Since the 
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number of patients with T3/T4 tumours was greater in those patients with right-sided tumours 
it may be that more tumour invasiveness accounted for the association between right-sided 
tumour location and the systemic inflammatory response and outcome. 
In the present study, there was no association between tumour location and CSS or OS in the 
full cohort or within the adjuvant group. On univariate analysis in patients with colon cancer, 
tumour location (i.e. right or left) was not associated with CSS or OS or indeed in those 
patients with colon cancer who had undergone adjuvant chemotherapy. Moreover, results of 
the present study show that measures of systemic inflammation in patients with colon cancer 
in the adjuvant and non-adjuvant setting were independently prognostic for CSS. Population-
based studies (Meguid et al. 2008; Benedix et al. 2010), and outcomes of retrospectively 
analysed oncological trials of patients with metastatic CRC (Loupakis et al. 2015; Venook et 
al. 2016) have reported an increase in mortality for right-sided cancers however, results are 
conflicting (Weiss et al. 2016; Warschkow et al. 2016). Moreover, they did not adjust for 
confounders such as the systemic inflammatory response. Therefore, it is of interest that 
Renfro and co-workers reported that, in more than 22,000 patients from 28 randomised 
clinical trials of patients with metastatic colorectal cancer, an elevated systemic inflammatory 
response as evidenced by an absolute neutrophil count and the derived NLR was associated 
with early mortality whereas KRAS status, patient sex, individual sites of metastases, 
location of primary tumour (colon v rectum), and prior chemotherapy use did not appear to 
play a prognostic role (Renfro et al.2017). Additionally, a study evaluating the prognostic 
role of tumour location in stage III colon cancer patients (PETACC-8 trial) in the context of 
molecular markers reported right-sided tumour location was not associated with disease-free 
survival but was associated with shorter survival after relapse when disease became 
metastatic and with overall survival in both MSI-stable and unstable patients (Taieb et al. 
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2017); However, potential confounding factors such as the systemic inflammatory response 
was not taken into account.  
A potential limitation of the present study was that only 45% of patients with stage III 
colorectal cancer received adjuvant therapy. It is well recognised Glasgow Royal Infirmary 
serves an area of multiple deprivation. As a consequence, many patients have multiple 
comorbidities and this precludes the use of chemotherapy. Moreover, as the present study 
spans a period between 1997 and 2016, a period effect should be appreciated. In the present 
study this effect was demonstrated by the increase in the number of patients with stage III 
colorectal cancer who received adjuvant chemotherapy from 37% in the first decade to 51% 
in the latter decade. 
In conclusion, right-sided tumour location was associated with host characteristics, features 
of the tumour microenvironment and the systemic inflammatory response, but not survival in 
patients undergoing potentially curative surgery for stage I-III CRC. Future studies 
investigating the role of tumour location in a prognostic or predictive capacity should be 
aware of the potential confounding role that inflammatory responses may have in these 
patients. 
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Figure legends 
 
Table 1. Associations between right/left/rectal tumours and clinicopathological characteristic, 
systemic inflammation and the tumour microenvironment in patients undergoing elective 
surgery for stage I-III colorectal cancer 
 
Table 2. Associations between right/left/rectal tumours and clinicopathological characteristic, 
systemic inflammation and the tumour microenvironment in patients who have undergone 
adjuvant chemotherapy following elective surgery for stage I-III colorectal cancer
 All 
n=972 (%) 
Right 
n=389 (%) 
Left 
n=285 (%) 
Rectal 
n=298 (%) 
p 
      
Host Characteristics       
Age (n=972) <65                      
65-74 
>75 
314 (32) 
343 (35) 
315 (33) 
101 (26) 
135 (35) 
153 (39) 
101 (36) 
98 (34) 
86 (30) 
112 (38) 
110 (37) 
76 (25) 
0.001 
Sex (n=972) Female 
Male 
438 (45) 
534 (55) 
188 (48) 
201 (52) 
132 (46) 
153 (54) 
118 (40) 
180 (60) 
0.065 
ASA status* (n=907) 1 
2 
3 
4 
162 (18) 
406 (45) 
302 (33) 
37 (4) 
52 (14) 
164 (44) 
138 (37) 
17 (5) 
48 (19) 
113 (44) 
82 (32) 
12 (5) 
90 (23) 
179 (46) 
115 (29) 
9 (2) 
0.088 
 
Tumour Characteristics       
T stage (n=969) 1-2 
3 
4 
207 (21) 
531 (55) 
231 (24) 
57 (15) 
216 (56) 
115 (29) 
65 (23) 
150 (53) 
69 (24) 
85 (29) 
165 (55) 
47 (16) 
<0.001 
N stage (n=971) 0 
1 
2 
617 (64) 
259 (26) 
95 (10) 
248 (64) 
101 (26) 
39 (10) 
192 (67) 
71 (25) 
22 (8) 
177 (59) 
87 (29) 
34 (11) 
0.320 
 
Table 1. Associations between right/left/rectal tumours and clinicopathological characteristic, systemic inflammation and the tumour 
microenvironment in patients undergoing elective surgery for stage I-III colorectal cancer  
 
 
TNM stage (n=971) I 
II 
III 
178 (18) 
437 (45) 
356 (37) 
53 (14) 
194 (50) 
142 (36) 
58 (20) 
134 (47) 
93 (33) 
67 (23) 
109 (37) 
121 (40) 
0.002 
Tumour differentiation (n=961) Mod/well 
Poor 
870 (90) 
91 (10) 
323 (84) 
62 (16) 
272 (96) 
9 (4) 
275 (93) 
20 (7) 
<0.001 
Venous invasion (n=971) No 
Yes 
486 (50) 
485 (50) 
180 (46) 
208 (54) 
162 (57) 
123 (43) 
144 (48) 
154 (52) 
0.021 
Margin involvement (n=971 No 
Yes 
919 (95) 
52 (5) 
370 (95) 
18 (5) 
271 (95) 
14 (5) 
278 (93) 
20 (7) 
0.466 
Necrosis 
 
Absent  
Present  
191 (58) 
138 (42) 
70 (58) 
51 (42) 
57 (54) 
49 (46) 
64 (63) 
38 (37) 
0.422 
MMR (n=228) Competent 
Deficient 
193 (85) 
35 (15) 
65 (75) 
22 (25) 
 
57 (89) 
7 (11) 
71 (92) 
6 (8) 
0.005 
BRAF (n=221) Wild-type 
V600E 
mutation 
169 (77) 
52 (23) 
61 (73) 
23 (27) 
50 (78) 
14 (22) 
58 (80) 
15 (20) 
0.566 
Tumour microenvironment       
Klintrup-Mäkinen grade 
(n=353) 
Weak 
Strong 
233 (66) 
120 (34) 
 
88 (70) 
37 (30) 
73 (64) 
42 (36) 
72 (64) 
41 (36) 
0.431 
Tumour stroma percentage 
(n=302) 
Low 
High 
228 (76) 
74 (24) 
92 (78) 
26 (22) 
71 (76) 
22 (24) 
65 (71) 
26 (29) 
0.543 
CD3+ margin density  (n=260) Low 
High 
148 (57) 
112 (43) 
54 (59) 
38 (41) 
36 (48) 
39 (52) 
58 (62) 
35 (38) 
0.160 
CD3+ cancer cell nest density 
(n=270) 
Low 
High 
173 (64) 
97 (36) 
55 (57) 
42 (43) 
47 (62) 
29 (38) 
83 (74) 
29 (26) 
0.048 
CD8+ margin density  (n=257) Low 
High 
150 (58) 
107 (42) 
53 (60) 
35 (40) 
38 (50) 
38 (50) 
59 (63) 
34 (37) 
0.194 
CD8+ cancer cell nest density 
(n=266) 
Low 
High 
185 (70) 
81 (30) 
63 (68) 
30 (32) 
52 (68) 
25 (32) 
70 (73) 
26 (27) 
 
0.666 
Systemic inflammation       
mGPS (n=926) 0 
1 
2 
658 (71) 
163 (18) 
105 (11) 
235 (64) 
69 (19) 
62 (17) 
201 (75) 
44 (16) 
25 (9) 
222 (77) 
50 (17) 
18 (6) 
<0.001 
Neutrophil:Lymphocyte ratio  
(n=814) 
Low 
High 
708 (87) 
106 (13) 
283 (85) 
51 (15) 
201 (90) 
23 (10) 
224 (88) 
32 (12) 
0.214 
 
Neutrophil:Platelet score  
(n=817) 
0 
1 
2 
667 (82) 
116 (14) 
34 (4) 
239 (72) 
71 (21) 
23 (7) 
204 (87) 
23 (10) 
7 (3) 
224 (90) 
22 (8) 
4 (2) 
<0.001 
 
 
Lymphocyte:monocyte ratio  Low 155 (16) 80 (21) 39 (14) 36 (12) 0.005 
*ASA: American Society of Anesthesiology physical status classification 
(n=972) High 817 (84) 309 (79) 246 (86) 262 (88) 
Adjuvant therapy (n=970) 
1997-2006 
 
2007-2016 
 
No 
Yes 
 
No 
Yes 
 
286 (78) 
86 (22) 
409 (68) 
189 (32) 
 
107 (84) 
21 (16) 
184 (61) 
75 (29) 
 
92 (78) 
26 (22) 
125 (75) 
42 (25) 
 
87 (69) 
39 (31) 
100 (58) 
72 (42) 
 
 
 
0.632 
 
5-year CSS % (SE) 
 
  79 (3) 83 (3) 76 (3) 0.377 
5-year OS % (SE) 
 
  66 (3) 71 (3) 67 (3) 0.205 
 All 
n=275 (%) 
Right 
n=96 (%) 
Left 
n=68 (%) 
Rectal 
n=111 (%) 
p 
      
Host Characteristics      
Age (n=275) <65                      
65-74 
>75 
144 (52) 
101 (37) 
30 (11) 
44 (46) 
39 (41) 
13 (13) 
39 (57) 
23 (34) 
6 (9) 
61 (55) 
39 (35) 
11 (10) 
0.583 
Sex (n=275) Female 
Male 
121 (44) 
154 (56) 
43 (45) 
53 (55) 
36 (53) 
32 (47) 
42 (38) 
69 (62) 
0.139 
 
ASA status* (n=256) 1 
2 
3 
4 
70 (27) 
119 (47) 
62 (24) 
5 (2) 
23 (25) 
46 (50) 
20 (22) 
3 (3) 
20 (32) 
29 (46) 
13 (20) 
1 (2) 
27 (27) 
44 (44) 
29 (28) 
1 (1) 
0.711 
Tumour Characteristics       
T stage (n=275) 1-2 
3 
4 
22 (9) 
163 (59) 
 90 (32) 
1 (1) 
50 (52) 
45 (47) 
8 (12) 
37 (54) 
23 (34) 
13 (12) 
76 (68) 
22 (20) 
 
<0.001 
N stage (n=275) 0 
1 
85 (31) 
134 (49) 
31 (32) 
46 (48) 
23 (34) 
3 (53) 
37 (28) 
52 (47) 
0.398 
Table 2. Associations between right/left/rectal tumours and clinicopathological characteristic, systemic inflammation and the tumour 
microenvironment in patients who have undergone adjuvant chemotherapy following elective surgery for stage I-III colorectal cancer 
 
2 56 (20) 19 (20) 9 (13) 28 (25) 
TNM stage (n=275) I 
II 
III 
3 (1) 
81 (30) 
191 (70) 
0 (0) 
30 (31) 
66 (69) 
0 (0) 
23 (34) 
45 (66) 
3 (3) 
28 (25) 
80 (72) 
0.141 
Tumour differentiation (n=274) Mod/well 
Poor 
244 (89) 
30 (11) 
81 (84) 
15 (16) 
65 (96) 
3 (4) 
98 (89) 
12 (11) 
0.058 
Venous invasion (n=275) No 
Yes 
92 (34) 
183 (66) 
23 (24) 
73 (76) 
24 (35) 
44 (65) 
45 (41) 
66 (59) 
0.036 
 Margin involvement (n=275) No 
Yes 
246 (90) 
29 (10) 
88 (92) 
8 (8) 
62 (91) 
6 (9) 
96 (87) 
15 (13) 
0.423 
Necrosis (n=87) 
 
Absent  
Present  
47 (54) 
40 (46) 
11 (48) 
12 (52) 
16 (57) 
12 (43) 
20 (56) 
16 (44) 
0.779 
MMR (n=66) Competent 
Deficient 
58 (88) 
8 (12) 
19 (86) 
3 (14) 
18 (95) 
1 (5) 
21 (84) 
4 (16) 
0.509 
 
BRAF (n=62) Wild-type 
V600E 
mutatation 
46 (74) 
16 (26) 
15 (75) 
5 (25) 
13 (65) 
7 (35) 
18 (82) 
4 (18) 
0.460 
Tumour microenvironment 
 
     
Klintrup-Mäkinen grade 
(n=102) 
Weak 
Strong 
30 (29) 
72 (71) 
10 (40) 
15 (60) 
10 (31) 
22 (69) 
10 (22) 
35 (78) 
0.285 
Tumour stroma percentage 
(n=79) 
Low 
High 
54 (68) 
25 (32) 
15 (68) 
7 (32) 
18 (72) 
7 (28) 
21 (66) 
11 (34) 
0.875 
CD3+ margin density (n=71) Low 
High 
42 (59) 
29 (41) 
9 (47) 
10 (53) 
10 (46) 
12 (54) 
23 (77) 
7 (23) 
0.033 
CD3+ cancer cell nest density 
(n=73) 
Low 
High 
58 (80) 
15 (20) 
12 (60) 
8 (40) 
17 (77) 
5 (23) 
29 (94) 
2 (6) 
0.012 
CD8+ margin density (n=71) Low 
High 
37 (52) 
34 (48) 
11 (58) 
8 (42) 
9 (43) 
12 (57) 
17 (55) 
14 (45) 
0.586 
CD8+ cancer cell nest density 
(n=73)  
Low 
High 
55 (75) 
18 (25) 
16 (76) 
5 (24) 
14 (67) 
7 (33) 
25 (81) 
6 (19) 
0.522 
 
 
Systemic inflammation       
mGPS (n=257) 0 
1 
2 
190 (74) 
47 (18) 
20 (8) 
56 (68) 
19 (23) 
8 (9) 
49 (75) 
11 (17) 
5 (8) 
85 (78) 
17 (16) 
7 (6) 
0.597 
 
 
Neutrophil:Lymphocyte ratio  
(n=249) 
 
Low 
High 
217 (87) 
32 (13) 
80 (88) 
11 (12) 
53 (93) 
 4 (7) 
84 (83) 
17 (17) 
0.183 
Neutrophil:Platelet score 
(n=239) 
0 
1 
2 
189 (79) 
40 (17) 
10 (4) 
63 (70) 
23 (26) 
4 (4) 
46 (85) 
5 (9) 
3 (6) 
80 (84) 
12 (13) 
3 (3) 
0.066 
ASA: American Society of Anesthesiology physical status classification 
Lymphocyte:monocyte ratio 
(n=275) 
Low 
High 
39 (14) 
236 (86) 
17 (18) 
79 (82) 
5 (7) 
63 (93) 
17 (15) 
94 (85) 
0.128 
5-year CSS % (SE) 
 
  80 (5) 85 (5) 7 (5) 0.302 
5-year OS % (SE) 
 
  74 (5) 85 (5) 66 (5) 0.076 
